Literature DB >> 23105867

Circulating vascular endothelial growth factor and nitric oxide in patients with liver cirrhosis: A possible association with liver function impairment.

Mohamed Ahmed Abdelmoaty1, Ahmed Mohamed Bogdady, Mervat Mohamed Attia, Nayel Abdelhamed Zaky.   

Abstract

Hemodynamic disorders of liver cirrhosis complicated with portal hypertension are associated with an increased angiogenesis in animal model of portal hypertension and cirrhosis which were linked to increased expression of vascular endothelial growth factor (VEGF) and nitric oxide (NO). The aim of study was to evaluate the serum concentration of VEGF and total nitric oxide (NO) in liver cirrhosis and the possible association with the degree of liver insufficiency. VEGF and NO were measured in serum of 64 patients with liver cirrhosis by ELISA and spectrophotometry respectively. The significant increase of serum VEGF was observed in liver cirrhosis compared to healthy individuals as well as serum NO (106.1 ± 66.7 vs. 41.5 ± 6 pg/mL, P < 0.05; 113.5 ± 65.8 vs. 20.8 ± 3.8 μmol/l, P< 0.001, respectively). Serum VEGF and NO showed significant associations with biochemical indices of liver function and with Child-pugh score where they were increased respectively to the degree of liver insufficiency. A significant association of raised serum NO in early stage of portal hypertension reflect its benefit in early expect of portal hypertension but, high serum VEGF in late stage may reflect its prognostic value in liver cirrhosis.

Entities:  

Keywords:  Liver cirrhosis; Nitric oxide; Portal hypertension; Vascular Endothelial Growth Factor

Year:  2009        PMID: 23105867      PMCID: PMC3453055          DOI: 10.1007/s12291-009-0071-5

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  39 in total

1.  Nitric oxide: a physiologic mediator of penile erection.

Authors:  A L Burnett; C J Lowenstein; D S Bredt; T S Chang; S H Snyder
Journal:  Science       Date:  1992-07-17       Impact factor: 47.728

Review 2.  The 1991 Ulf von Euler Lecture. The L-arginine: nitric oxide pathway.

Authors:  S Moncada
Journal:  Acta Physiol Scand       Date:  1992-07

3.  Role of endothelium-derived relaxing factor in parasympathetic coronary vasodilation.

Authors:  T P Broten; J K Miyashiro; S Moncada; E O Feigl
Journal:  Am J Physiol       Date:  1992-05

Review 4.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

5.  Correction of hypertension by normalization of endothelial levels of fibroblast growth factor and nitric oxide synthase in spontaneously hypertensive rats.

Authors:  P Cuevas; M García-Calvo; F Carceller; D Reimers; M Zazo; B Cuevas; I Muñoz-Willery; V Martínez-Coso; S Lamas; G Giménez-Gallego
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  Increased angiogenesis in portal hypertensive rats: role of nitric oxide.

Authors:  L T Sumanovski; E Battegay; M Stumm; M van der Kooij; C C Sieber
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

7.  Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis.

Authors:  R G Kilbourn; A Jubran; S S Gross; O W Griffith; R Levi; J Adams; R F Lodato
Journal:  Biochem Biophys Res Commun       Date:  1990-11-15       Impact factor: 3.575

8.  Hyperdynamic circulation in cirrhosis: a role for nitric oxide?

Authors:  P Vallance; S Moncada
Journal:  Lancet       Date:  1991-03-30       Impact factor: 79.321

9.  Plasma nitrate+nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats.

Authors:  R L van Bezooijen; I Que; A G Ederveen; H J Kloosterboer; S E Papapoulos; C W Löwik
Journal:  J Endocrinol       Date:  1998-10       Impact factor: 4.286

10.  L-arginine-dependent macrophage effector functions inhibit metabolic activity of Mycobacterium leprae.

Authors:  L B Adams; S G Franzblau; Z Vavrin; J B Hibbs; J L Krahenbuhl
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.